Targeting the Proteostasis Network for Mycobacterial Drug Discovery.,ACS Infectious Diseases

当前位置： X-MOL 学术 › ACS Infect. Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Targeting the Proteostasis Network for Mycobacterial Drug Discovery.
ACS Infectious Diseases ( IF 4.0 ) Pub Date : 2018-03-02 , DOI: 10.1021/acsinfecdis.7b00231
Tania J Lupoli ₁ , Julien Vaubourgeix ₁ , Kristin Burns-Huang ₁ , Ben Gold ₁

Affiliation

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains one of the world's deadliest infectious diseases and urgently requires new antibiotics to treat drug-resistant strains and to decrease the duration of therapy. During infection, Mtb encounters numerous stresses associated with host immunity, including hypoxia, reactive oxygen and nitrogen species, mild acidity, nutrient starvation, and metal sequestration and intoxication. The Mtb proteostasis network, composed of chaperones, proteases, and a eukaryotic-like proteasome, provides protection from stresses and chemistries of host immunity by maintaining the integrity of the mycobacterial proteome. In this Review, we explore the proteostasis network as a noncanonical target for antibacterial drug discovery.

中文翻译：

定位于Proteostasis网络用于分枝杆菌药物发现。

由结核分枝杆菌（Mtb）引起的结核病（TB）仍然是世界上最致命的传染病之一，迫切需要新的抗生素来治疗耐药菌株并缩短治疗时间。在感染期间，Mtb会遇到许多与宿主免疫相关的压力，包括低氧，活性氧和氮物种，弱酸度，营养缺乏，金属螯合和中毒。由伴侣蛋白，蛋白酶和类似真核生物的蛋白酶体组成的Mtb蛋白质稳态网络通过保持分枝杆菌蛋白质组的完整性，提供了免受宿主免疫力压力和化学作用的保护。在这篇综述中，我们探讨了蛋白稳态网络作为抗菌药物发现的非经典靶标。

更新日期：2018-02-21

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11